Affibody Presents at Anglonordic Life Science

Pressmeddelanden   •   Maj 21, 2018 09:00 CEST

Solna, Sweden, May 21, 2018. Affibody AB (“Affibody”), a clinical stage biopharmaceutical company developing a portfolio of innovative drug projects, today announced that it is presenting the company at Anglonordic Life Science conference, a UK and Nordic life science conference.

Interim Report – January to March 2018

Pressmeddelanden   •   Maj 18, 2018 09:00 CEST

Affibody Medical AB (publ) (“Affibody” or “the Company”), a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™, today issued its Interim Report for the first quarter 2018.

Affibody Presents at Bio€quity Europe

Pressmeddelanden   •   Maj 11, 2018 09:00 CEST

Solna, Sweden, May 11, 2018. Affibody AB (“Affibody”), a clinical stage biopharmaceutical company developing a portfolio of innovative drug projects, today announced that it is presenting the company at Bio€quity Europe, an investor and partnering event.

Kallelse till årsstämma

Pressmeddelanden   •   Maj 09, 2018 09:00 CEST

Aktieägarna i Affibody Medical AB (publ) kallas härmed till årsstämma onsdagen den 13 juni 2018 klockan 13.00 i bolagets lokaler, Gunnar Asplunds allé 24, Solna.

Affibody Announces First Psoriasis Patients Dosed in a Phase II Clinical Trial of ABY-035

Pressmeddelanden   •   Mar 21, 2018 08:00 CET

Solna, Sweden, March 21, 2018. Affibody AB (“Affibody”), a clinical stage biopharmaceutical company developing a portfolio of innovative drug projects, today announced dosing of the first patients in a Phase II proof-of-concept study of ABY-035 in patients with moderate-to-severe psoriasis.

Affibody Announces First Dosing in a Phase I Trial of ABY-039 for Autoimmune Diseases

Pressmeddelanden   •   Mar 13, 2018 08:00 CET

Solna, Sweden, March 13, 2018. Affibody AB (“Affibody”), a clinical stage biopharmaceutical company developing a portfolio of innovative drug projects, today announced first dosing in a Phase I proof-of-principle study of ABY-039, a potential best-in-class therapy for the treatment of B-cell driven autoimmune diseases.

Affibody Raises SEK 200m in Rights Issue

Pressmeddelanden   •   Mar 08, 2018 08:00 CET

Solna, Sweden, March 8, 2018. Affibody AB (“Affibody”), a clinical stage biopharmaceutical company developing a portfolio of innovative drug projects, today announced the outcome of the rights issue that was decided at the EGM on November 23, 2017.

Affibody Announces Participation in the CellNova Center

Pressmeddelanden   •   Feb 26, 2018 08:30 CET

Solna, Sweden, February 26, 2018. Affibody AB (“Affibody”), a clinical stage biopharmaceutical company developing a portfolio of innovative drug projects, today announced its participation in the CellNova Center.

Year End Report 2017

Pressmeddelanden   •   Feb 23, 2018 08:01 CET

Affibody Medical AB (publ) (“Affibody” or “the Company”), a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™, today issued its Interim Report for the fourth quarter 2017.

Bästa aktieägare i Affibody Medical AB

Nyheter   •   Dec 01, 2017 08:15 CET

Vid extra bolagsstämma i bolaget den 23 november i år beslöts att genomföra en nyemission av aktier i bolaget.

Bilder & Videor 1 bild

Kontaktpersoner 4 kontaktpersoner

Om Affibody

Developing Next Generation Biopharmaceuticals

Affibody is a clinical stage Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™.

The company operates a focused experimental medicine model and currently has four clinical or late stage preclinical proprietary programs. The first three are therapeutic programs that targets psoriasis, B-cell driven autoimmune diseases, and liver diseases respectively. The fourth program is a diagnostic imaging program that is directed primarily towards metastatic breast cancer.

In addition, to its portfolio of innovative drug projects the company offers the half-life extension technology, Albumod™, for outlicensing.

Affibody has ongoing commercial relationships with several companies such as AbClon, Biotest, Daewoong, Daiichi Sankyo, GE Healthcare, and Swedish Orphan Biovitrum.

Adress

  • Affibody
  • Gunnar Asplunds Allé 24
  • SE-171 69 SOLNA